<VariationArchive RecordType="classified" VariationID="40114" VariationName="NC_000004.11:g.88957372-?_89042944+?dup" VariationType="Duplication" Accession="VCV000040114" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-08-06" DateCreated="2017-04-29" MostRecentSubmission="2017-04-29">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="48615" VariationID="40114">
      <GeneList>
        <Gene Symbol="PKD2" FullName="polycystin 2, transient receptor potential cation channel" GeneID="5311" HGNC_ID="HGNC:9009" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>4q22.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="88007635" stop="88077777" display_start="88007635" display_stop="88077777" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="88928798" stop="88998930" display_start="88928798" display_stop="88998930" Strand="+" />
          </Location>
          <OMIM>173910</OMIM>
          <Haploinsufficiency last_evaluated="2012-07-06" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PKD2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2012-07-06" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PKD2">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000004.11:g.88957372-?_89042944+?dup</Name>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>4q21-q23</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="88957372" stop="88957372" display_start="88957372" display_stop="88957372" variantLength="1" />
      </Location>
      <OtherNameList>
        <Name>EX3DUP</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.11" sequenceAccession="NC_000004" sequenceVersion="11" change="g.88957372-?_89042944+?dup" Assembly="GRCh37">
            <Expression>NC_000004.11:g.88957372-?_89042944+?dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="173910.0010" DB="OMIM" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">85.6 kb duplication beginning at exon 3 of gene PKD2 and ending at exon 6 of gene ABCG2, plus flanking intronic sequences.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000004.11:g.88957372-?_89042944+?dup AND Polycystic kidney disease 2" Accession="RCV000033172" Version="19">
        <ClassifiedConditionList TraitSetID="3718">
          <ClassifiedCondition DB="MedGen" ID="C2751306">Polycystic kidney disease 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2011-09-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2011-09-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-04-29" MostRecentSubmission="2017-04-29">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">21719175</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3718" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6943" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">POLYCYSTIC KIDNEY DISEASE, ADULT, TYPE II</ElementValue>
                <XRef Type="MIM" ID="613095" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POLYCYSTIC KIDNEY DISEASE 2 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE</ElementValue>
                <XRef Type="MIM" ID="613095" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Polycystic kidney disease 2</ElementValue>
                <XRef ID="MONDO:0013131" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PKD2</ElementValue>
                <XRef Type="MIM" ID="613095" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">APKD2</ElementValue>
                <XRef Type="MIM" ID="613095" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Autosomal dominant polycystic kidney disease (ADPKD) is generally a late-onset multisystem disorder characterized by bilateral kidney cysts, liver cysts, and an increased risk of intracranial aneurysms. Other manifestations include: cysts in the pancreas, seminal vesicles, and arachnoid membrane; dilatation of the aortic root and dissection of the thoracic aorta; mitral valve prolapse; and abdominal wall hernias. Kidney manifestations include early-onset hypertension, kidney pain, and kidney insufficiency. Approximately 50% of individuals with ADPKD have end-stage kidney disease (ESKD) by age 60 years. The prevalence of liver cysts increases with age and occasionally results in clinically significant severe polycystic liver disease (PLD), most often in females. Overall, the prevalence of intracranial aneurysms is fivefold higher than in the general population and further increased in those with a positive family history of aneurysms or subarachnoid hemorrhage. There is substantial variability in the severity of kidney disease and other extra-kidney manifestations.</Attribute>
                <XRef ID="NBK1246" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301424</ID>
                <ID Source="BookShelf">NBK1246</ID>
              </Citation>
              <XRef ID="C2751306" DB="MedGen" />
              <XRef ID="MONDO:0013131" DB="MONDO" />
              <XRef Type="MIM" ID="613095" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="95079" SubmissionDate="2017-04-26" DateLastUpdated="2017-04-29" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="173910.0010_POLYCYSTIC KIDNEY DISEASE 2" title="PKD2, EX3DUP_POLYCYSTIC KIDNEY DISEASE 2" />
        <ClinVarAccession Accession="SCV000056954" DateUpdated="2017-04-29" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2011-09-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a 64-year-old woman with polycystic kidney disease-2 (PKD2; 613095), Bataille et al. (2011) identified a heterozygous duplication of exon 3 and the exon 3/intron boundary of the PKD2 gene, predicted to result in haploinsufficiency of PKD2. Her affected sister also carried the mutation. Family history revealed 6 additional affected family members, but they were not tested for the mutation. In addition to PKD2, the proband had situs inversus totalis, complete inversion of the thoracic large vessels, and a left-sided liver, consistent with a laterality defect. None of her 3 affected sisters had a laterality defect.</Attribute>
              <Citation>
                <ID Source="PubMed">21719175</ID>
              </Citation>
              <XRef DB="OMIM" ID="613095" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PKD2" />
          </GeneList>
          <Name>PKD2, EX3DUP</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">EX3DUP</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="173910.0010" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">POLYCYSTIC KIDNEY DISEASE 2</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="95079" TraitType="Disease" MappingType="Name" MappingValue="POLYCYSTIC KIDNEY DISEASE 2" MappingRef="Preferred">
        <MedGen CUI="C2751306" Name="Polycystic kidney disease 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

